OpenBiome will continue operating normally and remains committed to providing safe and continued access to #FMT for patients not responding to standard therapies. Learn more in our press release.
OpenBiome will continue operating normally and remains committed to providing safe and continued access to #FMT for patients not responding to standard therapies. Learn more in our press release. https://t.co/bD5KnuVnKZ— OpenBiome (@OpenBiome) December 1, 2022
from a donor, assuming their doctor will do that. We assumed FDA would hold off on this until one or more #microbiome restoration therapies were approved. They did not. #FMT has been very hard to get since #COVID19 and this will make it much harder. /2
from a donor, assuming their doctor will do that. We assumed FDA would hold off on this until one or more #microbiome restoration therapies were approved. They did not. #FMT has been very hard to get since #COVID19 and this will make it much harder. /2— Christian John Lillis (@ChristianLillis) November 30, 2022
The @US_FDA released its final guidance on #FMT for #Cdiff not responding to standard therapies. It prohibits the existence stool banks like @OpenBiome that are not part of a hospital with a laboratory but leaves the ability for a person to received donat
The @US_FDA released its final guidance on #FMT for #Cdiff not responding to standard therapies. It prohibits the existence stool banks like @OpenBiome that are not part of a hospital with a laboratory but leaves the ability for a person to received donated stool /1— Christian John Lillis (@ChristianLillis) November 30, 2022
Sherri Bocchini on Twitter: "RT @paiPad: We're looking for stool! Help support Canada's very first Pediatric FMT Stool Bank. Special thanks to @hamhealth for generously…" / Twitter
We're looking for stool! Help support Canada's very first Pediatric FMT Stool Bank. Special thanks to @hamhealth for generously supporting innovations in clinical care @mch_childrens. Kids 3-18yo, got stool? Let us know! #fmt #pediatrics #cDifficile pic.twitter.com/oqe4XUcYQ8— Nikhil Pai, MD CNSC FRCPC FAAP (@paiPad) December 4, 2022
Judge upholds order banning B.C. naturopath from making fecal transplants for autistic kids
A B.C. Supreme Court judge has upheld a ban meant to prevent a Fraser Valley naturopath from manufacturing, advertising and selling pills and enemas made from human feces for use on autistic children
FDA Approves First-Ever Fecal Microbiota, RBX2660, for C Difficile Recurrence - Contagionlive.com
Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.
At Novel Biome, we understand the importance of preparing the gut microbiome for FMT. We offer personalized pre-treatment along with one-on-one support from our physician assistant to ensure the best possible outcome for FMT. #fmt #guthealth #health #
At Novel Biome, we understand the importance of preparing the gut microbiome for FMT. We offer personalized pre-treatment along with one-on-one support from our physician assistant to ensure the best possible outcome for FMT. #fmt #guthealth #health #gut #asd #autism pic.twitter.com/qcTipOBgBR— Novel Biome (@NovelBiome) November 25, 2022
The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment
In the past few decades, great progress has been achieved in the understanding of microbiome-cancer interactions. However, most of the studies have focused on the gut microbiome, ignoring how other microbiomes interact with tumors. Emerging evidence suggests that in many types of cancers, such as lung cancer, pancreatic cancer, and colorectal cancer, the intratumoral microbiome plays a significant role. In addition, accumulating evidence suggests that intratumoral microbes have multiple effects on the biological behavior of tumors, for example, regulating tumor initiation and progression and altering the tumor response to chemotherapy and immunotherapy. However, to fully understand the role of the intratumoral microbiome in cancer, further investigation of the effects and mechanisms is still needed. This review discusses the role of intratumoral bacteria in tumorigenesis and tumor progression, recurrence and metastasis, as well as their effect on cancer prognosis and treatment outcome, and summarizes the relevant mechanisms.
Is fecal transplant a solution to prevent antibiotic resistance in immunocompromised patients?
According to a French-Italian study, the efficacy and safety of fecal microbiota transplant have been confirmed for the treatment of multi-drug resistant bacterial infections, even in immunocompromised patients.
Starting #FALKSYMPOSIUM230 with an incredible talk from @h_sokol from #microbiome basic concepts trough #FMT to tryptophan metabolism as a new therapeutic opportunity in #IBD A 20 year trip is opening new ways of thinking @geteccu #SomosGeteccu @BettenworthDb #GerardRogler pic.twitter.com/NoherKVnal— Fernando Gomollón (@fgomollon) November 25, 2022
What else can we do? #FMT may seem like a solution but may be unsafe in certain patient populations. Need to better understand host-pathogen interactions 🧍🦠#EASLStudio #AntimicrobialResistance #WAAW #LiverTWitter pic.twitter.com/2hiN7DpkEy— EASL Education (@EASLedu) November 23, 2022
Take-home messages from Blount that show the future of microbiome-based therapeutics is bright and this new modality of treatments could be a game-changer for patients struggling with C. difficile infection @Rebiotix @FerringMBiome @esnm_eu #GMFHCoverag
Take-home messages from Blount that show the future of microbiome-based therapeutics is bright and this new modality of treatments could be a game-changer for patients struggling with C. difficile infection @Rebiotix @FerringMBiome @esnm_eu #GMFHCoverage pic.twitter.com/lnDlF1zl4Y— GutMicrobiota Health (@GMFHx) November 22, 2022
Fecal microbiota transplantations and the role of bacteriophages
The accumulating evidence that bacteriophages play roles in FMT efficacy has attracted considerable interest. Better characterization of bacteriophages and understanding of their underlying mechanisms in FMT are warranted.
#GMFH2023 has an excellent program in store for you. Don’t miss it!✅ Next-generation probiotics: single strains and consortia✅ Fecal microbiota transplantation✅ Diet and prebiotics✅ Microbiota-derived molecules@esnm_eu @AmerGastroAssn https://t.co/5u0d4XqkWZ— GutMicrobiota Health (@GMFHx) November 22, 2022
Frontiers | Early life microbiota transplantation from highly feed-efficient broiler improved weight gain by reshaping the gut microbiota in laying chicken
Starting phase of laying chicken life is the building stone for rearing and production stages. Since, fecal microbial transplantation (FMT) regulates the gut microbial diversity and affects the productive performance of the bird. The aim of this study is to evaluate the effect of FMT from feed-efficient broiler chicken could program the diversity of gut microbiota and growth of recipient native slow growing egg-laying chicks. For this, a total of 150 (one-day-old) Jing Hong chicks were randomly assigned into two groups, each group consisted of 5 replicates (n = 15 bird/ replicate). The control group (CON) and FMT recipient birds (FMT) fed on basal diet, the FMT group received an oral daily dose of FMT prepared from Cobb-500 chickens. The FMT performed from the 1d to 28d of age, through the experimental period, feed intake and body weight were recorded weekly. At the end of a 28-day trial, carcass traits were assessed and cecal samples were collected for microbiome assessment via 16S rRNA-based metagenomic analysis to characterize the diversity and functions of microbial communities. The data were statistically analyzed using R software. Body weight and body weight gain increased, and FCR decreased (p = 0.01) in FMT group. The relative abundance of Firmicutes and the Firmicutes/Bacteroidetes (F/B) ratio were increased due to FMT administration (p = 0.01). A higher relative abundance of Lactobacillus, Lactococcus, and Bifidobacterium were presented in the FMT group. Meanwhil...
Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma - PubMed
Strategies to modify the gut microbiome in cancer patients using fecal microbiota transplantation (FMT) have gained momentum as a therapeutic intervention. However, how FMT impacts innate-like, antimicrobial T lymphocytes is unclear. In this study, we assessed peripheral blood (PB) mucosa-associated …
Integrative analysis of microbiome and metabolome data obtained from human fecal samples is important for moving the field forward. This data resource allows researchers to easily obtain multiple fully integrated microbiome-metabolome datasets
Integrative analysis of microbiome and metabolome data obtained from human fecal samples is important for moving the field forward. This data resource allows researchers to easily obtain multiple fully integrated microbiome-metabolome datasets https://t.co/OzHWrwQFYP— GutMicrobiota Health (@GMFHx) November 17, 2022
At number 2 (63 mentions) is this RCT first online in August in @Gut_BMJ on #FMT + anti-inflammatory diet for mild-to-moderate ulcerative #colitis, by Kedia et al. https://t.co/t5LHeG9YbX pic.twitter.com/QqJFOiqzWd— Hugh Thomas (@HepatologyHugh) November 15, 2022
Recognition and attitudes of Korean physicians toward fecal microbiota transplantation: a survey study - PubMed
Two-thirds of Korean physicians had experience of performing FMT, and many performed FMT for recurrent CDI. The results of this study will prove useful to researchers and practitioners in FMT in Korea.
614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
Background Microbiome-based interventions with fecal microbiota transplant (FMT) from treatment responders (R) have shown promising results in re-sensitizing anti-PD-1-refractory melanoma patients to anti-PD1 therapy. However, it is not currently known whether FMT can be used to prevent primary resistance. Here, we report results from the first phase I clinical trial ([NCT03772899][1]) that combines FMT with anti-PD1 therapy in anti-PD1-naïve melanoma patients.
Methods Twenty patients with advanced disease were treated with FMT with capsules from healthy donors one week before the standard of care anti-PD-1. A total of three donors were used. Fecal microbiota was profiled with 16S rRNA and metagenomics sequencing. 1H-NMR/SMolESY was used to measure plasma metabolites, and flow cytometry was performed on PBMCs. Additionally, FMT in avatar murine models was performed.
Results The median age was 75.5 years, and eight were female. The median follow-up time was 12.2 months. No unexpected toxicities or grade 3/4 toxicities were observed with FMT. Grade 3 immune-related adverse events included nephritis, pneumonitis, and vasculitis. ORR was 65% (13/20), of which 3 were CR. Clinical benefit rate (includes SD lasting 6 months) was 75% (15/20). There was no correlation between outcomes/toxicities and donors. Microbiome profiling revealed positive engraftment of all patients one week after FMT; however, sustainable engraftment was only observed in R at one month and maintained at three months. At the taxa level, R had enrichment of Eubacterium rectale , Eubacterium ramuleus , and Firmicutes while a loss of Hungatella . Metabolomics analysis uncovered that succinate levels were lower in R at baseline. A significant fold change increase in plasma propionate between pre- and post-FMT was observed in R but not non-responders (NR). Immune profiling showed an increase in conventional effector CD8+ T-cells and an increase in CD38+CD8+ Mucosa-associated invariant T (MAIT) cells in R compared to NR post-FMT. Avatar mouse models in germ-free and antibiotic-treated mice confirmed our clinical observations in that pre-FMT stool from both NR and R patients did not induce a response to anti-PD1 therapy. However, the post-FMT stool from R or FMT using donor feces sensitized B16-OVA and MCA-205 tumors to anti-PD1. Post FMT alpha diversity in responder mice correlated with increased intratumor memory CD8+ T-cells, TIM3+ T-cells, and stronger anti-PD-1 response.
Conclusions Our findings show that combining FMT from healthy donors with anti-PD1 potentially reduces primary resistance to immunotherapy. Successful engraftment of donor microbiota in patients correlated with better outcomes, and this was corroborated by translational experiments.
Acknowledgements This work was funded by the Lotte and John Hecht memorial foundation, an impact grant from the Canadian Cancer Society, medical oncology research funds at Western University, and the London Health Sciences Foundation.
Trial Registration NCT03772899
Ethics Approval This study was approved by the Ethics Research Board (REB) at Western University, CHUM hospital, and The Jewish General Hospital. REB # 113131
All participants signed informed consent before participating in the trial.
[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03772899&atom=%2Fjitc%2F10%2FSuppl_2%2FA645.atom
Is "number needed to convince" a new term for #FMT?Joined @HepatologyHugh to discuss EarlyFMT, FMT for 1st/2nd #Cdiff, featured in @LancetGastroHep podcast! 👇🏻Give it listen, if you are keen behind trial insights and our thoughts! https://t.co/dBucQ7MJu0— Simon MD Baunwall (@SMDBaunwall) November 10, 2022
Great session 🦠 #microbiome #diet before poster reception #SITC22 and feeding our own friends in the gut with fibers! 🥦🍇🥕Improving #CancerImmunotherapy by manipulating gut microbiome 🔬including #FMT Dr.Thomas Gajewski @UCCancerCenter @mcquadeMDLAc @GalMarkel @AlexCMcPherson pic.twitter.com/PMMqNUFWxM— NCICCR_VaccineBranch (@NCICCR_VB) November 10, 2022
